Drinking water arsenic in Utah: A cohort mortality study

Environmental Health Perspectives

Volumn 107, Issue 5, 1999, Pages 359-365

  Lewis, Denise Riedel ^a   Southwick, J Wanless ^b   Ouellet Hellstrom, Rita ^b   Rench, Jerry ^b,c   Calderon, Rebecca L ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b SRA Technologies Inc   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Arsenic; Cancer; Cohort studies; Drinking water; Epidemiologic studies; Mortality; Noncancer; Standardized mortality ratio; United States; Utah

Indexed keywords

ARSENIC; DRINKING WATER;

ADULT; AGED; ARTICLE; BIOSTATISTICS; CANCER; COR PULMONALE; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHRITIS; NEPHROSIS; PERICARDITIS; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; WATER ANALYSIS; WATER CONTAMINATION; WATER QUALITY;

EID: 0032816816     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107359     Document Type: Article

References (62)

1. Safe Water Drinking Act Amendments. 42 U.S.C. 300g-1 (b) (12) (A) (iv). Washington, DC:U.S. Government Printing Office, 1996.
2. Tseng WP, Chu HM, How SW, Fang JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40:453-463 (1968).
3. Tseng W-P. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109-119 (1977).
4. Morton W, Starr G, Pohl D, Stoner J, Wagner S, Weswig P. Skin cancer and water arsenic in Lane County, Oregon. Cancer 37:2523-2532 (1976).
5. Harrington JM, Middaugh JP, Morse DL, Housworth J. A survey of a population exposed to high concentrations of arsenic in well water in Fairbanks, Alaska. Am J Epidemiol 108:377-385 (1978).
6. Kreiss K, Zack MM, Feldman RG, Niles CA, Chirico-Post J, Sax DS. Neurologic evaluation of a population exposed to arsenic in Alaskan well water. Arch Environ Hearth 38:166-121 (1983).
7. Valentine JL. Review of health assessments for US/Canada populations exposed to arsenic in drinking water. In: Arsenic Exposure and Health (a special issue of Environmental Geochemistry and Health, Vol 16) (Chappell WR, Abernathy CO, Cothern CR, eds). Surrey, UK:Laws and Stimson Associates, 1994;139-152.
8. Wong O, Whorton MD, Foliari DE, Lowengart R. An ecologic study of skin cancer and environmental arsenic exposure. Int Arch Occup Environ Health 64: 235-241 (1992).
9. Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol 141:523-530 (1995).
10. Engel RR, Smith AH. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Hearlh 49:418-427 (1994).
11. Aschengrau A, Zierler S, Cohen A. Quality of community drinking water and the occurrence of spontaneous abortion. Arch Environ Health 44(5):283-289 (1989).
12. Zierler S, Theodore M, Cohen A, Rothman K. Chemical quality of maternal drinking water and congenital heart disease. Int J Epidemiol 17:589-594 (1988).
13. Feinglass EJ. Arsenic intoxication from well water in the United States. N Engl J Med 288:828-830 (1973).
14. Southwick JW, Western AE, Beck MM, Whitley J, Isaacs R. Community Health Associated with Arsenic in Drinking Water in Millard County, Utah. EPA Publications no EPA-600/S1-81-064. Cincinnati, OH:EPA Health Effects Research Laboratory, 1982.
15. Warner ML, Moore LE, Smith MT, Kalman DA, Fanning E, Smith AH. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol Biomarker Prev 3:583-590 (1994).
16. Valberg PA, Beck BD, Boardman PD, Cohen JT. Likelihood ratio analysis of skin cancer prevalence associated with arsenic in drinking water in the USA. Environ Geochem Health 20:61-66 (1998).
17. Stegman MS, Aaron WS, eds. ICD-9-CM Code Book Volumes 1, 2, and 3. Reston, VA:St. Anthony Publishing, 1995.
18. Lewis DR, Southwick JW, Scanlan LP, Rench J, Calderon R. The feasibility of conducting epidemiologic studies of waterborne arsenic. A mortality study in Millard County, Utah. J Environ Health 60:14-19 (1998).
19. Chen C-J, Hsueh Y-M, Lai M-S, Shyu P, Chen S-Y, Wu M-M, Kuo T-L, Tai T-Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60 (1995).
20. Chen C-J, Chiou H-Y, Chiang M-H, Lin L-J, Tai T-Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. ArteriosclerThromb Vasc Biol 16:504-510 (1996).
21. SAS Institute, Inc. SAS Version 6.11. Cary, NC:SAS, 1995.
22. Rothman KJ, Greenland S. Introduction to Categorical Statistics. In: Modern Epidemiology (Rothman KJ, Greenland S, eds). 2nd ed. Philadelphia:Lippincott-Raven Publishers, 1998;234-236.
23. Marsh GM, Preininger M, Ehland J, Caplan R, Bearden A, CoChien H, Paik M. OCMAP, OCMAP/PC. Mainframe and Microcomputer Version 2.0. Pittsburgh, PA:University of Pittsburgh, 1989.
24. Chatterjee A, Das D, Mandal BK, Chowdhury TR, Samanta G, Chakraborti D. Arsenic in ground water in six districts of West Bengal, India: the biggest arsenic calamity in the world. Part I: arsenic species in drinking water and urine of the affected people. Analyst 120:643-650 (1995).
25. Chen C-J, Chuang Y-C, Lin T-M, Wu H-Y. Malignant neoplasms among residents of a blackfoot disease endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45:5895-5899 (1985).
26. Hopenhayn-Rich C, Biggs ML, Fuchs A, Bergoglio R, Tello EE, Nicolli H, Smith A. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117-1124 (1996).
27. Guo H-R, Chen C-J, Greene HL. Arsenic in drinking water and cancers: a brief descriptive review of Taiwan studies. In: Arsenic Exposure and Health (a special issue of Environmental Geochemistry and Health Vol 16) (Chappell WR, Abernathy CO, Cothern CR, eds). Surrey, UK:Laws and Stimson Associates, 1994;129-138.
28. Chen C-J, Chuang Y-C, You S-L, Lin T-M, Wu H-Y. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 53:399-405 (1986).
29. Chen C-J, Wu M-M, Lee S-S, Wang J-D, Cheng S-H, Wu H-Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8:452-460 (1988).
30. Chen C-H, Wang C-J. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50:5470-5474 (1990).
31. Chen C-J, Chen C-W, Wu M-M, Kuo T-L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888-892 (1992).
32. Chiang H-S, Guo H-R, Hong C-L, Lin S-M, Lee E-F. The incidence of bladder cancer in the black foot disease endemic area in Taiwan. Br J Urology 71:274-278 (1993).
33. Chiou H-Y, Hsueh Y-M, Liaw K-G, Horng S-F, Chiang M-H, Pu Y-S, Lin J-S, Huang C-H, Chen C-J. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55:1296-1300 (1995).
34. Smith A, Goycolea M, Hague R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660-669 (1998).
35. Wu M-M, Kuo T-L, Hwang Y-H, Chen C-J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular disease. Am J Epidemiol 130:1123-1131 (1989).
36. Chiou H-Y, Huang W-I, Su C-L, Chang S-F, Hsu Y-H, Chen C-J. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28:1717-1723 (1997).
37. Lai M-S, Hsueh Y-M, Chien C-J, Shyu M-P, Chen S-Y, Kuo T-L, Wu M-M, Tai T-Y. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol 139: 484-492 (1994).
38. Rahman M, Tondel M, Ahmad SA, Axelson O. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol 148:198-203 (1998).
39. Valentine JL, He S-Y, Reisbord LS, Lachenbruch PA. Health response by questionnaire in arsenic-exposed populations. J Clin Epidemiol 45:487-494 (1992).
40. Andelman JB, Barnett M. Feasibility study to relate arsenic in drinking water to skin cancer in the United States. In: Environmental Epidemiology (FC Kopfler, GF Craun, eds). Chelsea, MI:Lewis Publishers, Inc., 1986;89-107.
41. Guo H-R, Valberg PA. Evaluation of the validity of the U.S. EPA's cancer risk assessment of arsenic for low-level exposures: a likelihood ratio approach. Environ Geochem Health 19:133-141 (1997).
42. Pontius FW. Uncertainties drive arsenic rule delay. J Am Water Works Assoc 87:12, 150 (1995).
43. Borgono JM, Vincent P, Venturino H, Infante A. Arsenic in the drinking water of the city of Antofagasta: epidemiological and clinical study before and after the installation of the treatment plant. Environ Health Perspect 19:103-105 (1977).
44. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 314:488-500 (1986).
45. Hansen ES. Shared risk factors for cancer and atherogenesis - a review of the epidemiological evidence. Mutat Res 239:163-179 (1990).
46. American Lung Association. Trends in Cigarette Smoking. New York:American Lung Association, Epidemiology and Statistics Unit, 1998.
47. Utah Department of Health, Health Education, Behavioral Risk Factor Surveillance System (BRFSS). Unpublished data.
48. Lyon JL, Gardner K, Gress RE. Cancer incidence among Mormons and non-Mormons in Utah (United States) 1971-1985. Cancer Causes Control 5:149-156 (1994).
49. Ross RK, Schottenfeld D. Prostate cancer. In: Cancer Epidemiology and Prevention, 2nd ed. (Schottenfeld D, Fraumeni JF, eds). New York:Oxford University Press, 1996;1180-1206.
50. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents, Vol VII. Lyon:International Agency for Research on Cancer, 1997.
51. Segi M. Age-adjusted death rates for cancer for selected sites in 52 countries in 1973. Segi, Japan:Segi Institute of Cancer Epidemiology, 1978.
52. Lyon JL, Klauber MR, Gardner JW, Smart CR. Cancer incidence in Mormons and non-Mormons in Utah, 1966-1970. N Engl J Med 294:129-133 (1976).
53. Woolf CM. An investigation of the familial aspects of cancer of the prostate. Cancer 13:739-743 (1960).
54. Scotto J, Fears TR, Kraemer KH, Fraumeni JF. Non-melanoma skin cancer. In: Cancer Epidemiology and Prevention, 2nd ed (Schottenfeld J, Fraumeni JF, eds). New York:Oxford University Press, 1996;1313-1330.
55. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II: The Design and Analysis of Cohort Studies. Lyon:International Agency for Research on Cancer, 1987;25-26,41.
56. Enterline P, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer: a reanalysis. Am J Epidemiol 125:929-938 (1987).
57. Simonato L, Moulin JJ, Javelaud B, Ferro G, Wild P, Winkelman R, Saracci R. A retrospective mortality study of workers exposed to arsenic in a gold mine and refinery in France. Am J Ind Med 25:625-633 (1994).
58. Branson JM, Patrick WJ. Fixation, transformation, and mobilization of arsenic in sediments. Environ Sci Technol 20:450-459 (1987).
59. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1:43-46 (1990).
60. Yamauchi H, Yamamura Y. Concentration and chemical species of arsenic in human tissue. Bull Environ Contam Toxicol 31:267-277 (1983).
61. Gerhardsson L, Dahlgren E, Eriksson A, Lagerkvist BEA, Lundstrom J, Nordberg GF. Fatal arsenic poisoning - a case report. Scand J Work Environ Health 14:130-133 (1988).
62. Lerman S, Clarkson TW. The metabolism of arsenite and arsenate by the rat. Fundam Appl Toxicol 3:309-314 (1983).